1-4 of 4
W. Douglas Figg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

Katie E. Hebron, Xiaolin Wan, Jacob S. Roth, David J. Liewehr, Nancy E. Sealover, William J.E. Frye, Angela Kim, Stacey Stauffer, Olivia L. Perkins, Wenyue Sun, Kristine A. Isanogle, Christina M. Robinson, Amy James, Parirokh Awasthi, Priya Shankarappa, Xiaoling Luo, Haiyan Lei, Donna Butcher, Roberta Smith, Elijah F. Edmondson, Jin-Qiu Chen, Noemi Kedei, Cody J. Peer, Jack F. Shern, W. Douglas Figg, Lu Chen, Matthew D. Hall, Simone Difilippantonio, Frederic G. Barr, Robert L. Kortum, Robert W. Robey, Angelina V. Vaseva, Javed Khan, Marielle E. Yohe
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 472–487.
https://doi.org/10.1158/1078-0432.CCR-22-1646
Published: 17 January 2023
View article titled, The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Open the PDF for The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models in another window
Includes: Supplementary data
Journal Articles

Abstract IA023: Therapeutic efficacy of trametinib and ganitumab in RAS-mutated rhabdomyosarcoma

Marielle E. Yohe, Katie E. Hebron, Xiaolin Wan, Jacob S. Roth, David J. Liewehr, Nancy E. Sealover, Stacey Stauffer, Olivia Feehan-Nelson, Wenyue Sun, Kristine A. Isanogle, Christina M. Robinson, Amy James, Parirokh Awasthi, Priya Shankarappa, Xiaoling Liu, Haiyan Lei, Donna Butcher, Roberta Smith, Elijah F. Edmonson, Jin-Qui Chen, Noemi Kedei, Cody S. Peer, Jack F. Shern, W. Douglas Figg, Lu Chen, Matthew D. Hall, Simone Difillipantonio, Frederic G. Barr, Robert L. Kortum, Angelina V. Vaseva, Javed Khan
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): IA023.
https://doi.org/10.1158/1557-3265.SARCOMAS22-IA023
Published: 15 September 2022
View article titled, Abstract IA023: Therapeutic efficacy of trametinib and ganitumab in RAS-mutated rhabdomyosarcoma
Journal Articles

A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies

Jill Gilbert, Sharyn D. Baker, M. Katherine Bowling, Louise Grochow, W. Douglas Figg, Yelena Zabelina, Ross C. Donehower, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2292–2300.
Published: 01 August 2001
View article titled, A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies
Open the PDF for A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies in another window
Journal Articles

A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer

Raymond C. Bergan, Eddie Reed, Charles E. Myers, Donna Headlee, Otis Brawley, Hea-Kyoung Cho, W. Douglas Figg, Anne Tompkins, W. Marston Linehan, David Kohler, Seth M. Steinberg, Mikhail V. Blagosklonny
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2366–2373.
Published: 01 September 1999
View article titled, A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer
Open the PDF for A Phase II Study of High-Dose Tamoxifen in Patients with Hormone-refractory Prostate Cancer in another window